ClinicalTrials.gg
RecruitingNCT06958406Updated Apr 23, 2026

Neural Mechanism of Cerebrocardiac Syndrome Following Traumatic Brain Injury

An observational study in Traumatic Brain Injury and Cerebrocardiac Syndrome, sponsored by Shanghai 6th People's Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Shanghai 6th People's Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.

Planned enrollment
22nd of 34
90 · median 110
Started
2025
with 6 others
Observational
34 of 60
19 open now
Primary completion
2027-07
later than 21 of 29 live
Registered
50th of 60
by date
Lead sponsor
6 of 60
Shanghai 6th People's Hospital

Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 22nd largest by planned enrollment of the 34 observational ones that give a count, is one of 7 that started in 2025, is one of 34 observational ones, reaches primary completion later than 21 of the 29 other live ones, and was the 50th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Brain Injuries, Traumatic with a site in China, or all of them as a file.
02

Study summary

Cerebrocardiac syndrome (CCS), including myocardial injury, arrhythmia or heart failure is one of serious complications of traumatic brain injury (TBI), mostly occurs within seven days after TBI, which directly aggravates the brain damage and affects the prognosis of TBI patients. Accumulative evidences suggest that autonomic nervous system disorder is a key initiation point for CCS, but how TBI affects the specific action patterns is not yet clear. Therefore, elucidating the neural mechanisms of TBI-induced CCS, maintaining the central sympathetic-parasympathetic balance through novel interventions such as noninvasive brain stimulation, may fundamentally block the downstream peripheral mechanism, thus achieving effective prevention and treatment for CCS. Based on the current emerging research in brain connectomics and lesion-symptom mapping, we speculate that cerebral contusions can cause structural or functional disconnection of key nodes in the central autonomic nervous system regulatory network, thereby mediating the occurrence of TBI-induced CCS.

In this study, magnetic resonance imaging (MRI) or functional MRI (fMRI) examinations were performed in patients with mild or moderate TBI with aim to explore the association between structural and functional disconnection caused by cerebral contusion and TBI-induced CCS, and to screen out the neural anatomical structures to predict CCS following TBI, providing therapy targets for prevention and treatment of CCS.

03

Conditions studied

  • Traumatic Brain Injury
  • Cerebrocardiac Syndrome

Keywords

  • traumatic brain injury
  • cerebrocardiac syndrome
  • brain connectomics
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Traumatic brain injury patients and healthy volunteers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with isolated closed head trauma
  • Age 18-80 years old
  • Admitted to hospital within 24 hours of injury
  • Mild or moderate TBI (Glasgow Coma Scale score of 9-15)
  • Signed consent form

Exclusion criteria

Exclusion Criteria:

  • Severe TBI (Glasgow Coma Scale score of 3-8)
  • A history of stroke, TBI, intracranial tumor or surgery in the past 1 year
  • A history of coronary heart disease, structural heart disease and other primary heart diseases or suspected cardiac symptoms prior to injury
  • Causes of abnormal cardiac biomarkers such as renal insufficiency, severe anemia, sepsis, cardiotoxic drugs and so on
  • Not suitable for MRI examinations, such as pregnant women and those with metal implants in the body
  • Undergo surgery prior to MRI examinations or cardiac testing
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • TBI-CCS

    Patients with TBI-induced CCS, including myocardial injury, arrhythmia or heart failure.

  • Non TBI-CCS

    Patients with non TBI-induced CCS.

  • Normal control

    Normal healthy people.

06

What researchers measure

Primary outcomes

  1. Brain network evaluation by MRI

    MRI data of all participants are acquired within 3 days after enrollment, and the MRI scans include one or more of the following contents: 1. 3D T1-weighted images, which were acquired with a magnetization prepared rapid-acquisition gradient-echo sequence. 2. The resting state-fMRI data, acquired with an interleaved T2-weighted axial gradient-echo echoplanar imaging sequence. 3. DTI datasets, acquired using a fully-sampled spin-echo EPI sequence.

    Time frame: Within 3 days after enrollment

  2. Cardiac evaluation by ECG

    ECG data of all participants are acquired within 3 days after enrollment, and include resting and ambulatory ECG to detect arrhythmias, heart rate variability or myocardial ischemia. Specifically, arrhythmias include atrial fibrillation (irregular R-R intervals, absent P waves, fibrillatory waves), ventricular tachycardia (QRS \>120 ms, rapid rate, often no discernible P waves), heart blocks (1st degree: PR interval \>200 ms; 2nd degree: progressive PR prolongation until a QRS drops; 3rd degree: complete AV dissociation and atrial rate \> ventricular rate) and premature contractions (early beats with wide or narrow QRS). Heart rate variability is analyzed via R-R interval variability over time (24-hour Holter), and the indicators include Time-Domain (SDNN and RMSSD) and Frequency-Domain (LF/HF ratio). Myocardial ischemia indicators include ST segment depression ≥0.5 mm in ≥2 contiguous leads, ST elevation ≥1 mm in ≥2 contiguous leads, and inversion or hyperacute T waves.

    Time frame: Within 3 days after enrollment

  3. Cardiac evaluation by echocardiography

    Echocardiography data of all participants are acquired within 3 days after enrollment, in order to assess heart pumping function. Specifically, the key parameters assessed include ventricular function (ejection fraction: % of blood ejected per beat) and cardiac output quantification. The decline in the above indicators suggests heart ischemia or heart failure.

    Time frame: Within 3 days after enrollment

  4. Cardiac evaluation by blood testing-1

    Blood testing data of all participants are acquired within 3 days after enrollment and include several key cardiac biomarkers: myoglobin (normal: 14.3-65.8 μg/L), cardiac troponin I (cTnI, normal: 0-0.03 μg/L), cardiac troponin T (cTnT, normal: 0-0.1 μg/L), B-type natriuretic peptide (BNP, normal: 0-0.1 μg/L) and NT-proBNP (normal: \<0.3 μg/L). Specifically, elevated myoglobin is useful for early detection of myocardial infarction (MI); elevated cTnI and cTnT, especially with a rising/falling pattern, are gold standard for diagnosing MI; elevated BNP and NT-proBNP suggest heart failure (HF), especially BNP \>0.4 μg/L indicates severe HF.

    Time frame: Within 3 days after enrollment

  5. Cardiac evaluation by blood testing-2

    Blood testing data of all participants are acquired within 3 days after enrollment and include the following cardiac biomarkers: creatine kinase (CK, normal: 21-190 U/L ), CK-MB (normal: 0-25 U/L) and lactate dehydrogenase (LDH, normal: 114-240 U/L). Specifically, elevated CK and CK-MB suggest cardiac muscle injury; elevated LDH are useful for early detection of MI.

    Time frame: Within 3 days after enrollment

Secondary outcomes

  1. Clinical prognosis assessed by GOS score

    Glasgow Outcome Scale (GOS) score (1 = death; 2 = persistent vegetative state; 3 = severe disability; 4 = moderate disability; 5 = good but not necessarily complete recovery; unfavorable outcome was defined as score of ≤3, and favorable outcome was defined as a score of \>3)

    Time frame: One month, three and six months after trauma

  2. Neurological function assessed by mRS score

    Modified Rankin Scale (mRS) score (0 = no symptoms; 1 = no significant disability; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = dead; favorable outcome was defined as score of 0-2, and unfavorable outcome was defined as score of 3-6)

    Time frame: One month, three and six months after trauma

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 23 months is below that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
May 6, 2025
StartActual
Aug 10, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06958406
Lead sponsor
Shanghai 6th People's Hospital
Responsible party
Hao Chen, MD, PhD (Associate Professor, Chief Physician, Graduate Supervisor, Shanghai 6th People's Hospital) — Principal investigator
First posted
May 6, 2025
Start date
Aug 10, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Hao Chen, M.D., Ph.D.
Contact
hao.chen@shsmu.edu.cn
8602164369181 ext. 8405
Lai Wei, M.D.
Contact
WL990126@hotmail.com
8602164369181 ext. 8405
Hao Chen, M.D., Ph.D.
study director · Shanghai 6th Peoples' Hospital
Lai Wei, M.D.
principal investigator · Shanghai 6th Peoples' Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion